Obseva SA (NASDAQ:OBSV) Short Interest Update

Obseva SA (NASDAQ:OBSV) was the target of a significant drop in short interest during the month of September. As of September 30th, there was short interest totalling 290,800 shares, a drop of 33.4% from the August 30th total of 436,900 shares. Based on an average daily trading volume, of 44,400 shares, the short-interest ratio is presently 6.5 days. Approximately 1.5% of the shares of the company are short sold.

Several institutional investors and hedge funds have recently bought and sold shares of OBSV. Capital Investment Advisory Services LLC purchased a new position in shares of Obseva in the second quarter worth about $40,000. Renaissance Technologies LLC increased its stake in shares of Obseva by 7.6% in the second quarter. Renaissance Technologies LLC now owns 79,600 shares of the company’s stock worth $900,000 after purchasing an additional 5,600 shares in the last quarter. AXA increased its stake in shares of Obseva by 7.8% in the second quarter. AXA now owns 500,313 shares of the company’s stock worth $5,659,000 after purchasing an additional 36,356 shares in the last quarter. Morgan Stanley increased its stake in shares of Obseva by 358.6% in the second quarter. Morgan Stanley now owns 3,100 shares of the company’s stock worth $35,000 after purchasing an additional 2,424 shares in the last quarter. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Obseva by 263.6% in the second quarter. Cubist Systematic Strategies LLC now owns 3,272 shares of the company’s stock worth $37,000 after purchasing an additional 2,372 shares in the last quarter. Hedge funds and other institutional investors own 63.97% of the company’s stock.

Shares of OBSV traded up $0.35 during trading hours on Friday, hitting $7.96. The company’s stock had a trading volume of 47,094 shares, compared to its average volume of 38,084. The company has a market cap of $336.53 million, a price-to-earnings ratio of -4.17 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.67 and a quick ratio of 3.67. The business has a 50 day simple moving average of $8.95 and a two-hundred day simple moving average of $10.97. Obseva has a 52-week low of $7.14 and a 52-week high of $18.05.

Obseva (NASDAQ:OBSV) last posted its earnings results on Wednesday, August 7th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.22). Research analysts predict that Obseva will post -2.99 earnings per share for the current year.

A number of analysts recently issued reports on the stock. ValuEngine upgraded shares of Obseva from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Zacks Investment Research downgraded shares of Obseva from a “hold” rating to a “sell” rating in a report on Wednesday, July 31st. Credit Suisse Group decreased their price objective on shares of Obseva from $24.00 to $16.00 and set an “outperform” rating for the company in a report on Monday, July 29th. HC Wainwright restated a “buy” rating and set a $44.00 price objective on shares of Obseva in a report on Wednesday, September 4th. Finally, Wedbush restated an “outperform” rating and set a $38.00 price objective on shares of Obseva in a report on Thursday, July 18th. Two investment analysts have rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $27.75.

Obseva Company Profile

ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy. It is developing Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; Nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age.

Featured Story: Inflation

Receive News & Ratings for Obseva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obseva and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit